Alzheimer Disease Plasma Biomarkers in the Mid-Western Amish

Ping Wang[1*], Yeunjoo E. Song[1], Audrey Lynn[1,2], Kristy Miskimen[1], Alex Gulyayev [3,4], Michael B. Prough[3,4], Daniel A. Dorfsman[3,4], Renee A. Laux[1], Sarada L. Fuzzell[1], Sherri D. Hochstetler[1], Andrew F. Zaman[3], Larry D. Adams[3], Laura J. Caywood[3], Jason E. Clouse[3], Sharlene D. Herington[3], Patrice Whitehead[3], Yining Liu[5], Noel Moore[5], Paula Ogrocki[6,7], Alan J. Lerner[6,7], Anthony J. Griswold[3,4], Jeffery M. Vance[3,4], Michael L. Cuccaro[3,4], William K. Scott[3,4], Margaret A. Pericak-Vance[3,4], Jonathan L. Haines[1,2]

1. Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, 2103 Cornell Road, Cleveland, OH 44106, USA
2. Cleveland Institute for Computational Biology, 2103 Cornell Road, Cleveland, OH 44106, USA
3. John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, 1501 NW 10th Ave, Miami, FL 33136, USA
4. Dr. John T. Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, 1501 NW 10th Ave, Miami, FL 33136, USA
5. Department of Nutrition, School of Medicine, Case Western Reserve University, 2109 Adelbert Road, Cleveland, OH 44106, USA
6. Department of Neurology, University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, USA
7. Department of Neurology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106, USA

Correspondence

Ping Wang, MS

Email: pxw287@case.edu

Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University

Address: 1-326 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH 44106, USA

*** Ping Wang will handle correspondence at all stages of refereeing and publication, also post-publication.**

Jonathan L. Haines, PhD

Email: jlh213@case.edu

Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University

Address: 2-529 Wolstein Research Building, 2103 Cornell Road, Cleveland, OH 44106, USA

Structured Abstract

INTRODUCTION: Alzheimer disease (AD) plasma biomarkers are noninvasive measures of the key amyloid beta (Aβ) and tau pathologies. Validation and generalization studies are needed to fully understand their potential for AD prediction and diagnosis in the elderly population.

METHODS: In 1,067 Amish individuals aged ≥ 65, we measured plasma Aβ and tau to assess their relationships with AD-related outcomes.

RESULTS: Among Amish individuals with AD, plasma p-tau181 was significantly higher ($p = 0.04$), and plasma Aβ42/p-tau181 ratio was significantly lower ($p = 0.01$) than cognitively normal individuals. The association of AD with elevated p-tau181 was driven by APOE ε4 carriers (OR = 6.02, $p < 0.001$). Cluster analysis identified two subgroups defined by differing Aβ and tau levels, with the high-risk cluster having more APOE ε4 carriers ($p < 0.001$).

DISCUSSION: Plasma biomarkers, particularly p-tau181, Aβ42/Aβ40, and Aβ42/p-tau181 ratio, are promising surrogate biomarkers for AD-related pathology and clinical outcomes in the Amish.

1. Background

Alzheimer disease (AD) is the leading cause of dementia, affecting approximately 6.9 million Americans aged 65 and older.[1] The primary pathological hallmarks of AD include aggregates of amyloid beta (Aβ) plaques and tau tangles.[2,3] Biomarkers reflecting these biological changes are critical to diagnosing AD and monitoring disease progression.[4] Recent advances, including the approval of new AD therapeutics primarily targeting Aβ plaques,[5,6] have established biomarkers as essential screening tools to identify eligible individuals for novel treatments. Although brain Aβ and tau pathologies can be reliably quantified *in vivo* using neuroimaging and cerebrospinal fluid (CSF) measures, the high cost, low accessibility, and invasiveness of these tests hinder population-level application. Plasma biomarkers, in contrast, offer a promising solution by mitigating these limitations. They can serve as accessible blood-based surrogates for AD pathologies and facilitate the identification of individuals at the earliest disease stage when the treatments are most likely to be successful.

The Aβ42/Aβ40 ratio and phosphorylated tau protein at epitope 181 (p-tau181) are promising plasma biomarkers for capturing abnormal Aβ and tau buildup. Plasma Aβ42/Aβ40 and p-tau181 have demonstrated good accuracy in differentiating between image-confirmed amyloid-positive and amyloid-negative individuals, as well as between individuals who are cognitively normal, have mild cognitive impairment (MCI), or are clinically diagnosed with AD and other forms of dementia.[7-10] Circulating levels of these biomarkers are associated with neurodegeneration[11-18] and the severity of dementia;[19,20] they can also track disease progression and predict the onset of AD in

individuals who were cognitively normal or had mild symptoms.[11,15,16,21-26] However, most of these validation studies were conducted in clinical cohorts. A significant potential advantage of blood-based biomarkers is their ability to screen for AD pathological changes in at-risk populations at low burden and low cost. There is a great need to better understand the value of blood-based biomarkers in community-based elderly individuals.

We analyzed plasma biomarkers collected from the Amish communities in the Midwest (Ohio and Indiana), which present an ideal population for genetic studies of AD due to their unique genetic and cultural background.[27] The Amish, with their tendency to marry those of the same faith, show less genetic diversity than the general population. Moreover, they share relatively uniform environmental exposures, including similar lifestyles, education, diets, and health behaviors. Previous surveys indicated a lower prevalence of cognitive impairment in the Amish compared to the general population, despite lower levels of formal education.[28-31] However, AD plasma biomarkers have not been studied in the Amish. In this study, we focused on describing plasma Aβ42/Aβ40 and p-tau181 in relation to AD-related outcomes. Additional biomarkers, including the individual levels of plasma Aβ40, Aβ42, total tau (t-tau), and two Aβ/tau ratios (Aβ42/t-tau and Aβ42/p-tau181), were also investigated. Furthermore, we applied a clustering analysis using Aβ42/Aβ40 and p-tau181 to identify potential subgroups with unique biomarker profiles. This characterization and profiling of plasma biomarkers in the Amish will enhance our understanding of plasma biomarkers in the aging population.

2. Methods

2.1 Data Collection and Cognitive Testing

Data were collected from individuals enrolled in the Collaborative Amish Aging and Memory Project (CAAMP). CAAMP is a multi-center prospective study focusing on successful aging and dementia among the Amish population in Ohio and Indiana. The recruitment and ascertainment process for the CAAMP study has been previously described.[32,33] A door-to-door interview was conducted to collect blood samples and data on demographics, medical history, neuropsychological function, and social determinants. We re-assessed individuals who were cognitively normal or had mild cognitive impairment at two-year intervals, and additional blood samples were obtained if possible. Genealogical records were available in the Anabaptist Genealogy Database to determine the degree of relatedness among Amish individuals.[34] Genotype data were obtained from the Illumina Expanded Multi-Ethnic Genotyping Array (MEGAEX) with custom content or Illumina Global Screening Array (GSA). We confirmed the Apolipoprotein E (APOE) ε2/ε3/ε4 polymorphisms from the chip data and whole genome sequencing. All participants underwent a screening of cognitive function using the Modified Mini-Mental State Examination (3MS).[35] The 3MS score ranges from 0 to 100, and individuals with a lower 3MS score are more likely to have cognitive deficits or early-stage dementia. A subset of Amish individuals underwent more in-depth assessments, including the CERAD Word List Learning Test,[36] Verbal Fluency,[37] Trail Making Test (A and B),[38] Logical Memory,[39] and Multilingual Naming Test.[40]

2.2 Clinical outcomes

Based on medical history and cognitive measurements, a clinical adjudication team consisting of neurologists and neuropsychologists classified participants as cognitively unimpaired (CU), mild cognitive impairment (MCI), cognitively impaired but not AD (CINAD), or cognitively impaired related to AD (AD). For our analyses, individuals who were MCI, CINAD, and AD were grouped together as cognitively impaired (CI). We defined two AD-related binary outcomes: 1) the AD outcome by comparing the subset of AD individuals to those who were CU, and 2) the cognitive preservation (CP) outcome by comparing CU individuals to CI individuals. For analyses involving CI, we conducted a sensitivity analysis by excluding individuals with MCI from this group.

2.3 Plasma biomarkers and quality control

Biomarker data were obtained from frozen plasma samples stored in 500ul aliquots at -80 degrees. Samples were randomly assigned on each plate and run in duplicate. Concentrations of plasma Aβ40, Aβ42, and t-tau were measured using the Simoa™ Neurology 3-Plex A or Neurology 4-Plex E assays (Quanterix), whilst p-tau181 was measured using the Simoa™ P-tau181 Advantage V2 assay. Results for all Aβ and tau biomarkers were above the detection limit of the assays. To ensure the quality of biomarkers used for analyses, we performed quality control (QC) at the individual biomarker level (Supplemental Figure 1). We first matched the biomarker samples to clinical data in the Amish. Samples without a consensus diagnosis or from non-Amish individuals were excluded. Some individuals had duplicate results from

samples collected on the same date. In such cases, we excluded the set of results with a higher intra-assay coefficient of variation (CV). We then kept samples with a CV of less than 20%. Based on summary statistics and visualization, we evaluated samples for each biomarker on a case-by-case basis. The outlier for each biomarker was defined by the Median Absolute Deviation (MAD). This method is more robust in detecting outliers for skewed distributions due to its reliance on non-parametric measures of central tendency and variation.

2.4 Statistical analysis

From biomarkers that passed QC, we restricted our data to the most recently measured biomarkers for cross-sectional analysis. To compare differences in demographics, clinical features, and biomarkers between diagnostic groups (CU, MCI, CINAD, and AD), we used the Kruskal-Wallis test for continuous variables with non-parametric distributions. For categorical variables, we used either the Chi-square test or Fisher's exact test. We applied the Bonferroni method to correct for multiple comparisons in the post-hoc analysis.

Relationships between plasma biomarkers were estimated using the Spearman's rank correlation coefficient. Due to the skewed distributions of biomarker data, plasma biomarkers were log-transformed to better approximate normality and variance homogeneity. To study the association between each biomarker and AD, we applied logistic regression in individuals with AD and CU, adjusting for age at sample collection, age^2, sex, presence/absence of APOE ε4 alleles, time from specimen collection to

diagnosis, biomarker batches, and research center. To understand the predictive value of biomarkers for cognitive preservation (CP) in the CU individuals, we performed logistic regression in the CU and CI groups, adjusting for the covariates above but replacing APOE ε4 allele status with the presence/absence of APOE ε2. The interaction between biomarkers and APOE (ε4 or ε2) was included as an additional covariate in all multivariate analyses. We evaluated the performance of plasma biomarkers in classifying AD and CP using the receiver operating characteristic curve (ROC) analysis. The optimal cutoff value was determined by the Youden's Index. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and areas under the curve (AUC) were reported. We also applied the 10-fold cross-validation to assess the model's stability across different subsets of the data and ensure robust generalization.

To identify Amish subgroups, we applied the unsupervised K-medoids clustering approach using plasma Aβ42/Aβ40 and p-tau181. Potential confounding effects were addressed by regressing out the influences of age, sex, and research center using a quadratic regression model. Adjusted biomarkers were then inverse normalized for the clustering analysis. The distance matrix was calculated using the Euclidean distance. The K-medoids method is more robust in minimizing the distance between points in the same cluster. The primary analysis set the number of clusters at two to test if plasma Aβ42/Aβ40 and p-tau181 may split the Amish population into two groups. We also checked the optimal number of clusters derived from the elbow method and Silhouette score as a secondary analysis. Good clustering is indicated by the elbow point of the scree plot and a high average silhouette width. To interpret the cluster profiles, we

explored the differences in demographics and clinical features between clusters. We further evaluated the relationships between clusters and cognitive function after controlling for diagnosis, sex, age, age^2, research center, and APOE ε4 allele status. All statistical analyses were conducted in R (version 1.4.1717, https://www.r-project.org).

3. Results

3.1 Study population

After quality control, the cross-sectional data set consisted of 1,067 individuals for biomarker analysis. The average age was 81.2 ± 6.2 years. 50.4% of the individuals were from the Ohio research center, 40.9% were males, and 74.1% had eight years of education. The characteristics of these individuals by diagnostic groups (i.e., CU, MCI, CINAD, or AD) are presented in Table 1. Compared to CU individuals, individuals with AD or MCI were significantly older ($P_{Bonferroni} < 0.001$). 268 individuals carried at least one APOE ε4 allele, and comparing across diagnostic groups, 46.4% of the AD individuals were APOE ε4 carriers, which is significantly higher than the percentage of carriers in the CU ($P_{Bonferroni} < 0.001$) or MCI group ($P_{Bonferroni} = 0.003$).

3.2 Univariate analysis of plasma biomarkers

Detailed results of plasma biomarkers by consensus diagnosis are included in Supplemental Table 1. No significant differences were found in plasma amyloid biomarkers (i.e., Aβ40, Aβ42, Aβ42/Aβ40) between diagnostic groups. As shown in Figure 1, after adjusting for multiple comparisons, individuals in the AD group had a significantly higher level of plasma p-tau181 than CU individuals (2.1 ± 0.9 pg/mL vs.

1.9 ± 0.8 pg/mL, $P_{Bonferroni}$ = 0.04). For the ratio of plasma Aβ42/p-tau181, individuals with AD had significantly lower Aβ42/p-tau181 (3.6 ± 2.6) compared to individuals with CINAD (5.5 ± 22.9, $P_{Bonferroni}$ = 0.02) and CU (4.8 ± 2.9, $P_{Bonferroni}$ = 0.01). Plasma t-tau and Aβ42/t-tau ratio did not differ significantly between groups.

Among all individuals, the correlations between Aβ biomarkers were significant ($p < 0.05$), and plasma Aβ40 and Aβ42 had the strongest positive correlation (ρ = 0.83) (Supplemental Figure 2). t-tau and p-tau181 also were significantly correlated (ρ = 0.24, $p < 0.05$). Between plasma Aβ and tau biomarkers, t-tau had significant correlations with Aβ40 (ρ = 0.29, $p < 0.05$) and Aβ42 (ρ = 0.25, $p < 0.05$), but the correlations between p-tau181 and Aβ biomarkers were weak. Moderate to strong correlations (ρ ranging from 0.32 - 0.49) were found between the different ratios. The correlation matrix in CU individuals had a similar pattern. However, among individuals with AD, we found less significant correlations by *p*-values.

3.3 Multivariate analysis of plasma biomarkers and AD-related outcomes

We examined the relationships between each plasma biomarker and AD-related outcomes after adjusting for covariates, including age, age^2, sex, the presence of APOE (ε2 or ε4) alleles, time from specimen collection to diagnosis, biomarker batches, research center, and the interaction between biomarkers and APOE (Supplemental Table 2). No statistically significant associations were found between plasma biomarkers and AD in the multivariate analyses (Figure 2A). Amish individuals with AD tended to have lower Aβ biomarkers in the plasma, including Aβ42/Aβ40, Aβ40, and

Aβ42. The ratios of Aβ42/t-tau and Aβ42/p-tau181 showed similar trends of associations. In contrast, AD individuals were more likely to have a higher plasma t-tau. Interestingly, the association between p-tau181 and AD (OR = 0.77, 95% CI: 0.39 - 1.51, p = 0.44) was modulated by the interaction between p-tau181 and APOE ε4 (OR = 8.55, 95% CI: 2.69 - 28.92, p = 0.0004). After stratifying by APOE ε4 (Supplemental Table 3), p-tau181 was not significantly associated with AD among non-carriers (OR = 0.75, 95% CI: 0.38 - 1.94, p = 0.41). Nonetheless, among APOE ε4 carriers AD was strongly associated with increased levels of p-tau181 (OR = 6.02, 95% CI: 2.33 - 17.11, $p < 0.001$). As expected, for the cognitive preservation outcome (Figure 2B), plasma biomarkers essentially showed the opposite direction of associations compared to the results in the AD outcome. The strongest relationship was found between plasma Aβ42/Aβ40 and CP (OR = 1.81, 95% CI: 1.01 - 3.23, p = 0.05), which was no longer statistically significant in the sensitivity analysis excluding MCI from the CI group (Figure 2C). Notably, individuals with CP were significantly more likely to have decreased p-tau181 (OR = 0.58, 95% CI: 0.35 - 0.96, p = 0.04) and increased Aβ42/p-tau181 ratio (OR = 1.80, 95% CI: 1.18 - 2.76, p = 0.01) in the sensitivity analysis.

To evaluate the performance of plasma biomarkers in distinguishing AD from CU, we compared each model to a reference model (Supplemental Table 4). This reference model, adjusted for covariates of age, age^2, sex, research center, and time from sample collection to diagnosis, yielded an AUC of 0.64. While the PPV was high, the sensitivity, specificity, and NPV values were low. As expected, incorporating APOE ε4 into the reference model generated a higher AUC and sensitivity. Furthermore, the addition of

individual biomarkers generally improved the model's discriminative performance for AD, except for t-tau. The best model in predicting AD was the one using all biomarkers or Aβ42/p-tau (AUC = 0.83). For the cognitive preservation outcome, adding individual biomarkers to the reference model did not meaningfully enhance the model's performance. The most useful predictive model for CP was when APOE ε2 and all biomarkers were included (AUC = 0.71), followed by the one incorporating APOE ε2 and Aβ42/t-tau (AUC = 0.70). In the sensitivity analysis excluding MCI, models with APOE ε2 and individual biomarkers overall worked better with higher AUCs than analyses including MCI, except for t-tau (Supplemental Table 5). The predictive model for CP performed the best when APOE ε2 and all biomarkers (or Aβ42/pTau) were included (AUC = 0.77). In the 10-fold cross-validation of these models, the average performance matrices for each biomarker in classifying AD or CP were similar.

3.4 Clustering results using plasma Aβ42/Aβ40 and p-tau181

In the primary clustering analysis using a pre-fixed number of clusters (k = 2), Amish individuals can be divided into two subgroups based on plasma Aβ42/Aβ40 and p-tau181 (Figure 3). Cluster 1 (n = 382) showed a low-risk profile for AD characterized by elevated levels of plasma Aβ42/Aβ40 (0.06 ± 0.02) and reduced levels of p-tau181 (1.71 ± 0.63 pg/mL). In contrast, Cluster 2 (n = 294) presented a vastly different pattern with a higher burden of Aβ (decreased Aβ42/Aβ40) and tau (increased p-tau181), indicating a high-risk profile for AD. Notably, Aβ42 was significantly lower in Cluster 2 than Cluster 1 (7.17 ± 3.46 vs. 9.23 ± 3.64, $p < 0.001$). The concentration of plasma Aβ40 and t-tau, however, did not show significant differences between the two clusters.

The two clusters did not differ significantly by age, sex, research center, education, and history of smoking (Table 2). However, Cluster 2 contained significantly more APOE ε4 carriers ($p < 0.001$) and individuals with AD ($p = 0.04$) than Cluster 1. Upon further examination (Supplemental Table 6), we found no significant differences between the two clusters in the self-reported medical history of neurological disorders or cardiovascular risk factors, such as Parkinson's disease, multiple sclerosis, epilepsy, heart disease, diabetes, and hypertension. Cluster 1, however, had more individuals reporting a history of elevated lipids/cholesterol than Cluster 2 ($p = 0.02$). Although not significant, individuals with AD had a higher chance of being in Cluster 2 (OR = 1.55, 95% CI: 0.80 - 3.04) after controlling for age, age^2, sex, research center, and APOE (Supplemental Table 7). Meanwhile, individuals with cognitive preservation were less likely to appear in Cluster 2, especially when MCIs were excluded from the analysis (OR = 0.60, 95% CI: 0.41 - 0.88, $p = 0.01$). No significant associations were found between the two clusters when cognitive test results (e.g., 3MS, verbal fluency, working memory, logical memory, MINT) were examined individually.

In the secondary clustering analysis, the elbow and silhouette methods suggested an optimal number of three clusters in the Amish (Supplemental Figure 3). Between k = 2 and k = 3, the clustering results revealed a clearer distinction between Aβ and tau profiles, particularly in the distribution of moderate and low levels across individuals. At k = 3, the original Cluster 1 from the primary clustering analysis was evenly divided into two distinct subclusters: one cluster (n = 192) exhibited a profile of low Aβ risk,

characterized by the highest Aβ42/Aβ40 ratio (0.06 ± 0.02) and Aβ42 level (10.01 ± 3.95 pg/mL), but high Tau risk with a high p-tau181 level (2.20 ± 0.71pg/mL); the other cluster (n = 190) showed a moderate Aβ risk profile with slightly lower Aβ42/Aβ40 ratio of 0.05 ± 0.01 and Aβ42 level of 7.87 ± 3.16 pg/mL, alongside a low Tau risk evidenced by the lowest p-tau181 level of 1.41 ± 0.41 pg/mL. Individuals who were previously grouped together with low levels of Aβ and Tau exhibited greater differences in tau levels, resulting in their placement in distinct clusters. Similarly, Cluster 2 from the primary clustering analysis was distributed across all three clusters at K=3: the one characterized by a profile of low Aβ risk and high Tau risk (n = 34), another by a moderate Aβ risk and low Tau risk profile (n = 49), as described above. The remaining individuals (n = 211) retained a profile of high Aβ risk and high Tau risk, characterized by the lowest level of Aβ42 (7.05 ± 3.32 pg/mL) and Aβ42/Aβ40 ratio (0.04 ± 0.01), along with the highest level of p-tau181 (2.67 ± 0.72 pg/mL). This more refined clustering provides a nuanced differentiation between individuals with low Aβ but high tau levels and those with moderate Aβ and low tau levels.

As shown in Supplemental Table 8, Cluster 2 had a significantly lower level of p-tau181 than Cluster 1 and 3. From Cluster 1 to Cluster 3, there was a significantly increasing burden of amyloid suggested by decreasing levels of Aβ42/Aβ40 and Aβ42. In Cluster 3, 40.4% of individuals were APOE ε4 carriers, a proportion significantly higher compared to the other two clusters ($p < 0.001$). None of the medical histories differed significantly between clusters (Supplemental Table 9). There were no significant associations between AD-related outcomes and clusters after adjusting for age, age^2,

sex, research center, and the presence of APOE alleles (ε4 for AD and ε2 for CP). In models adjusting for the above covariates and diagnosis, Cluster 3 was associated with a prolonged completion of Trails Making B (beta = 15.8 seconds, 95% CI: 0.53 - 31.09, p = 0.04). However, this association did not survive multiple testing (Supplemental Table 10).

4. Discussion

In this cross-sectional study, we describe the characteristics of AD core plasma biomarkers in the Amish, including Aβ40, Aβ42, Aβ42/Aβ40, t-tau, p-tau181, Aβ42/t-tau, and Aβ42/p-tau181. Compared to cognitively unimpaired individuals, those with AD had significantly higher p-tau181 and lower Aβ42/p-tau181 ratio. We explored the value of these biomarkers by analyzing their associations with both AD and cognitive preservation outcomes, in which plasma p-tau181 emerged as the most promising biomarker, demonstrating a statistically significant association with AD among APOE ε4 carriers. Furthermore, p-tau181 and Aβ42/p-tau181 ratio were also associated with the CP outcome among individuals with CU, AD, and CINAD. Through the k-medoids approach, we first tested an a priori hypothesis that there were two Amish subgroups with unique Aβ and tau profiles using plasma Aβ42/Aβ40 and p-tau181. This clustering was refined when using three clusters. To our knowledge, this is the first study to summarize AD-related plasma biomarkers for amyloid-beta and tau pathologies in the Amish. Founder populations like the Amish, characterized by unique genetic homogeneity, reduced environmental variability, and a lower prevalence of common

confounding factors, offer a valuable opportunity to explore robust associations between biomarkers and AD risk and resilience.

In plasma, neither Aβ40, Aβ42, or Aβ42/Aβ40 differed significantly between diagnostic groups. However, as expected, Aβ42/Aβ40 emerges as a promising biomarker in associating with AD, surpassing the individual Aβ40 or Aβ42. The ratio can adjust for between-individual differences in total Aβ production, therefore, having higher concordance with brain amyloidosis.[41] Numerous studies have shown that plasma Aβ42/Aβ40 has a high correspondence with amyloid PET positivity,[42,43] and a lower Aβ42/Aβ40 ratio was significantly associated with the onset of AD and long-term cognitive deterioration.[44,45] Although not statistically significant, we observed inverse relationships between Aβ biomarkers and AD after adjusting for covariates, aligning with the previously reported trends. Notably, elevated plasma Aβ42/Aβ40 was associated with cognitive preservation in the Amish (OR = 1.81, $p = 0.05$), suggesting its potential use to differentiate normal aging and cognitive impairment.

We evaluated t-tau and p-tau181 to reflect neuronal damage and subsequent drainage of tau from the brain parenchyma to blood. We found that plasma p-tau181 was elevated in the Amish individuals with AD ($p = 0.04$). Furthermore, we found a significant interaction between AD and log-transformed p-tau181 and APOE ε4 in the multivariate regression model ($p < 0.001$). AD was associated with a higher level of p-tau181 only in APOE ε4 carriers (OR = 6.02, $p < 0.001$). The moderating effect of APOE ε4 on the association of AD and plasma p-tau181 was in line with previous studies,

wherein plasma p-tau181 levels were strongly associated with AD,[46] neurodegeneration,[46,47] memory deficits,[47] and cognitive decline,[48] almost exclusively in the APOE ε4 carriers. The mechanism by which APOE interacts with plasma p-tau181 is not clear. APOE ε4 may exacerbate tau pathology, possibly by affecting tau aggregation, phosphorylation, or tau-mediated neurodegeneration.[49,50] Overexpression of APOE ε4 in astrocytes can increase the phosphorylation and aggregation of tau within neurons.[51] APOE is also recognized for its role in modulating the blood-brain barrier (BBB); ε4 allele damages the integrity of the BBB, which may facilitate the escape of p-tau181 into CSF and plasma.[52] Notably, the correlation of APOE ε4 and tau is likely independent of Aβ pathology. Shi et al. showed that tau pathogenesis and tau-mediated neurodegeneration were more severe in mouse models transfected with the human ApoE4 gene without influence from Aβ.[53] Thus, regardless of the disease staging, APOE ε4 carriers with elevated p-tau181 may be more susceptible to the onset and progression of AD. Despite a significant positive correlation between t-tau and p-tau181 ($\rho = 0.24$, $p < 0.05$), t-tau did not vary much between diagnostic groups and had no associations with AD or cognitive preservation in the Amish. Additionally, regression models integrating t-tau performed the poorest in identifying AD or CP according to AUCs. Plasma t-tau is not specific to AD. Elevated t-tau levels can be observed in various neurodegenerative diseases and neurological conditions leading to neuronal damage.[54] Plasma t-tau is also age-dependent.[55,56] Individuals enrolled in this study were primarily older adults; the large overlap between normal aging and dementia may play a role in the non-significant findings for plasma t-tau in the Amish.

Since AD is characterized by multiple pathological changes, a combination of plasma biomarkers reflecting co-occurring pathology may be more powerful in classifying people at risk for AD diagnostically. In our models distinguishing between AD and CU, the model incorporating all biomarkers (i.e., Aβ40, Aβ42, Aβ42/Aβ40, t-tau, and p-tau181) outperformed the models using individual biomarkers alone based on AUCs. For the cognitive preservation outcome, we also observed improved AUCs and sensitivity values using all biomarkers. Interestingly, we found that plasma Aβ42/p-tau181 was a superior measure in classifying AD than individual biomarkers as well. Aβ42/p-tau181 was significantly decreased in the Amish individuals with AD (p = 0.01), suggesting concomitant AD pathology. Elevated Aβ42/p-tau181 ratio was associated with higher odds of cognitive preservation among CU and CI (i.e., CINAD and AD) individuals. Moreover, Aβ42/p-tau181 had similar discriminative capability for AD and CP compared to the models using all biomarkers, corroborating findings from previous studies that Aβ42/p-tau181 added discriminatory power over solitary Aβ42, t-tau and p-tau181 in separating AD from controls and other dementias.[57] [58] Our results provide additional evidence supporting the use of plasma Aβ42/p-tau181 to assess AD and cognitive preservation in the aging population.

Alternatively, we integrated plasma Aβ42/Aβ40 and p-tau181 in the clustering analysis to detect the heterogeneity in biomarker profiles regardless of diagnoses. Common methods for determining the optimal number of clusters, such as the elbow method and silhouette analysis, rely heavily on summary statistics (e.g., within-cluster sum of squares, average silhouette score). Such metrics may not effectively capture the

underlying clustering structure, especially in small datasets.[59] Additionally, small sample sizes amplify the risk of spurious results due to noise or outliers. Given the limited number of individuals in the Amish with both plasma Aβ42/Aβ40 and p-tau181 measurements, we chose k=2 as the primary clustering solution. This choice simplifies interpretation and provides clearer insights into the variability of biomarker profiles within the Amish population. Furthermore, using two clusters ensures larger cluster sizes, which enhances statistical power for subsequent analyses. The primary clustering analysis divided Amish individuals into two subgroups, with one group displaying a high-risk profile for AD-related pathology, evidenced by the decreased levels of Aβ42/Aβ40 and Aβ42 in combination with increased p-tau181. The other group featured a low-risk profile with relatively higher levels of Aβ42/Aβ40 and Aβ42, and a lower level of p-tau181. When separating the Amish into three clusters as indicated by the elbow plot and Silhouette width, individuals were further separated based on decremental levels of Aβ42/Aβ40 and Aβ42. Either way, the subgroup with the highest Aβ and tau burden consisted of a significantly higher proportion of APOE ε4 carriers ($p < 0.001$), and this group also tended to have more individuals with AD. The clusters did not differ significantly in age, sex, education, smoking, and medical history. While assessing the association between method-derived clusters and the Trails Making Test B, Cluster 3 with a high-risk profile for Aβ and tau had worse performance than individuals in Cluster 1 with a relatively lower risk for Aβ but still high risk for tau. Although this relationship did not survive the multiple comparisons, our data might suggest an independent association between Aβ and executive function. Previous studies in preclinical AD have shown the relationship between Aβ accumulation and executive function preceding

memory impairment,[60,61] implying the importance of early screening using both executive and memory measurements.

A few limitations should be acknowledged in this work. First, the Amish population is relatively small and is not representative of the general aging population with a European ancestry. Second, the clinical diagnosis was derived mainly from the medical history and cognitive measurements as the Amish do not have imaging or CSF data available, there might be a misclassification of diagnosis, especially for individuals with MCI or subtle impairments. Third, the plasma biomarker levels are only a proxy for AD pathologies in the brain. However, reliable assays are now available to measure extremely low levels of brain-derived proteins in blood samples[62,63] and alterations in plasma biomarkers are in accordance with the changes in CSF.[64] We applied rigorous quality control at the research center and biomarker level, but other pre-analytical factors should be taken into consideration while harmonizing biomarker data from different centers.[65] Lastly, the cross-sectional analysis only provided a snapshot of the associations between plasma biomarkers and AD-related outcomes; longitudinal data to understand the changes in plasma biomarkers over time are critical to monitor the development of AD. Despite these limitations, this study is novel in characterizing and profiling core AD plasma biomarkers in the elderly Amish population. Due to the reduced genetic diversity and relatively homogeneous environment, Amish may be an ideal population to study the genetics of plasma biomarkers to advance the understanding of AD pathophysiology. Examinations of genetic variants influencing plasma biomarkers in the Amish are underway.

5. Conclusions

In summary, plasma biomarkers, especially p-tau181, Aβ42/Aβ40, and Aβ42/p-tau181, are promising non-invasive indicators to distinguish Amish individuals with AD or cognitive impairments from those who are cognitively unimpaired. Additionally, we demonstrate that biomarker-guided clustering using Aβ42/Aβ40 and p-tau181 can identify individuals at various levels of risk for AD. These findings are important to screen for biomarker evidence of AD in older adults and potentially form homogenous subgroups that share similar disease mechanisms and treatment responses. Longitudinal studies are needed to validate the Aβ, tau, and neurodegeneration biomarkers in early detection and disease monitoring in the Amish and older population.

References

1. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). *Alzheimers Dement*. Dec 2021;17(12):1966-1975. doi:10.1002/alz.12362
2. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends in pharmacological sciences*. 1991;12:383-388.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-59. doi:10.1007/bf00308809
4. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May 2011;7(3):263-9. doi:10.1016/j.jalz.2011.03.005
5. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. *J Prev Alzheimers Dis*. 2022;9(2):197-210. doi:10.14283/jpad.2022.30
6. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*. Jan 5 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
7. Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry*. Jun 2022;93(6):651-658. doi:10.1136/jnnp-2021-327788

8. Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. *Neurology*. 2016;87(17):1827-1835.

9. Thijssen EH, Verberk IMW, Kindermans J, et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. *Alzheimers Dement (Amst)*. 2022;14(1):e12285. doi:10.1002/dad2.12285

10. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med*. Mar 2020;26(3):387-397. doi:10.1038/s41591-020-0762-2

11. de Wolf F, Ghanbari M, Licher S, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. *Brain*. 2020;143(4):1220-1232. doi:10.1093/brain/awaa054

12. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol*. May 1 2017;74(5):557-566. doi:10.1001/jamaneurol.2016.6117

13. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study. *The Lancet Neurology*. 2006;5(8):655-660.

14. Clark C, Lewczuk P, Kornhuber J, et al. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. *Alzheimers Res Ther*. Mar 25 2021;13(1):65. doi:10.1186/s13195-021-00805-8

15. Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. *Alzheimers Dement*. Jun 2022;18(6):1141-1154. doi:10.1002/alz.12447

16. Simrén J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimers Dement*. Jul 2021;17(7):1145-1156. doi:10.1002/alz.12283

17. Wang YL, Chen J, Du ZL, et al. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study. *Front Neurol*. 2021;12:695696. doi:10.3389/fneur.2021.695696

18. Smirnov DS, Ashton NJ, Blennow K, et al. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. *Acta Neuropathol*. Apr 2022;143(4):487-503. doi:10.1007/s00401-022-02408-5

19. Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimers Dement*. Aug 2018;14(8):989-997. doi:10.1016/j.jalz.2018.02.013

20. Soni H, Goyal MK, Sarma P, et al. Evaluation of Plasma Amyloid Peptides Aβ(1-40) and Aβ(1-42) as Diagnostic Biomarker of Alzheimer's Disease, its Association with Different Grades of Clinical Severity and 18F-Fluorodeoxyglucose Positron Emission Tomography Z score in the Indian Population: A Case-Control Study. *Indian J Nucl Med*. Oct-Dec 2021;36(4):391-397. doi:10.4103/ijnm.ijnm_50_21

21. Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly

populations. *Nature Communications*. 2021/06/11 2021;12(1):3555. doi:10.1038/s41467-021-23746-0

22. Stockmann J, Verberk IMW, Timmesfeld N, et al. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. *Alzheimer's Research & Therapy*. 2020/12/24 2020;12(1):169. doi:10.1186/s13195-020-00738-8

23. Chen SD, Huang YY, Shen XN, et al. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. *Transl Psychiatry*. Jun 12 2021;11(1):356. doi:10.1038/s41398-021-01476-7

24. Stockmann J, Verberk IMW, Timmesfeld N, et al. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. *Alzheimers Res Ther*. Dec 24 2020;12(1):169. doi:10.1186/s13195-020-00738-8

25. Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. *Nat Commun*. Jun 11 2021;12(1):3555. doi:10.1038/s41467-021-23746-0

26. Shen XN, Li JQ, Wang HF, et al. Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. *Alzheimers Dement (Amst)*. 2020;12(1):e12104. doi:10.1002/dad2.12104

27. van der Walt JM, Scott WK, Slifer S, et al. Maternal lineages and Alzheimer disease risk in the Old Order Amish. *Human genetics*. 2005/10// 2005;118(1):115-122. doi:10.1007/s00439-005-0032-x

28. Johnson C, Rybicki B, Brown G, Jackson C. PREVALENCE OF DEMENTIA IN THE AMISH-A 3-COUNTY SURVEY. JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH 111 MARKET PLACE, STE 840 …; 1993:645-645.

29. Pericak-Vance MA, Johnson CC, Rimmler JB, et al. Alzheimer's disease and apolipoprotein E-4 allele in an Amish population. *Ann Neurol*. Jun 1996;39(6):700-4. doi:10.1002/ana.410390605

30. Johnson CC, Rybicki BA, Brown G, et al. Cognitive impairment in the Amish: a four county survey. *International Journal of Epidemiology*. 1997;26(2):387-394. doi:10.1093/ije/26.2.387

31. Holder J, Warren AC. Prevalence of Alzheimer's disease and apolipoprotein E allele frequencies in the Old Order Amish. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 1998;10(1):100-102.

32. Edwards DRV, Gilbert JR, Jiang L, et al. Successful aging shows linkage to chromosomes 6, 7, and 14 in the Amish. *Annals of human genetics*. 2011;75(4):516-528.

33. Edwards DR, Gilbert JR, Hicks JE, et al. Linkage and association of successful aging to the 6q25 region in large Amish kindreds. *Age (Dordr)*. Aug 2013;35(4):1467-77. doi:10.1007/s11357-012-9447-1

34. Agarwala R, Biesecker LG, Tomlin JF, Schäffer AA. Towards a complete North American Anabaptist genealogy: A systematic approach to merging partially overlapping genealogy resources. *Am J Med Genet*. Sep 10 1999;86(2):156-61. doi:10.1002/(sici)1096-8628(19990910)86:2<156::aid-ajmg13>3.0.co;2-5

35. Teng EL, Chui HC. The modified mini-mental state (3MS) examination. *The Journal of clinical psychiatry*. 1987;

36. Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD): I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology*. 1989;

37. Tombaugh TN, Kozak J, Rees L. Normative Data Stratified by Age and Education for Two Measures of Verbal Fluency: FAS and Animal Naming. *Archives of Clinical Neuropsychology*. 1999/02/01/ 1999;14(2):167-177. doi:https://doi.org/10.1016/S0887-6177(97)00095-4

38. Reitan RM, Wolfson D. A selective and critical review of neuropsychological deficits and the frontal lobes. *Neuropsychology review*. 1994;4(3):161-198.

39. Wechsler D. Wechsler memory scale-revised. *Psychological Corporation*. 1987;

40. Gollan TH, Weissberger GH, Runnqvist E, Montoya RI, Cera CM. Self-ratings of Spoken Language Dominance: A Multi-Lingual Naming Test (MINT) and Preliminary Norms for Young and Aging Spanish-English Bilinguals. *Biling (Camb Engl)*. Jul 2012;15(3):594-615. doi:10.1017/s1366728911000332

41. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*. 2019;93(17):e1647-e1659.

42. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*. Oct 22 2019;93(17):e1647-e1659. doi:10.1212/wnl.0000000000008081

43. Jang H, Kim JS, Lee HJ, et al. Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in

a DPUK-KOREAN cohort. *Alzheimer's Research & Therapy*. 2021/10/22 2021;13(1):179. doi:10.1186/s13195-021-00911-7

44. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F. Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline: A Systematic Review and Meta-analysis. *Archives of Neurology*. 2012;69(7):824-831. doi:10.1001/archneurol.2011.1841

45. Seppälä TT, Herukka SK, Hänninen T, et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. *J Neurol Neurosurg Psychiatry*. Oct 2010;81(10):1123-7. doi:10.1136/jnnp.2010.205757

46. Salami A, Adolfsson R, Andersson M, et al. Association of APOE ε4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function. *J Alzheimers Dis*. 2022;85(3):1309-1320. doi:10.3233/jad-210673

47. Sanchez E, Wilkinson T, Coughlan GT, et al. The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease. *Alzheimer's & Dementia*. 2023;19(S15):e079202. doi:https://doi.org/10.1002/alz.079202

48. Wang S, Ke S, Liu S, Wang E, Pan T. APOE ε4 status and plasma p-tau181 interact to influence cognitive performance among non-demented older adults. *Neuroscience Letters*. 2023/02/06/ 2023;796:137052. doi:https://doi.org/10.1016/j.neulet.2023.137052

49. Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic

review. *Alzheimer's Research & Therapy*. 2020/11/04 2020;12(1):141. doi:10.1186/s13195-020-00712-4

50. Saroja SR, Gorbachev K, Julia T, Goate AM, Pereira AC. Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. *Proc Natl Acad Sci U S A*. Aug 23 2022;119(34):e2108870119. doi:10.1073/pnas.2108870119

51. Jablonski AM, Warren L, Usenovic M, et al. Astrocytic expression of the Alzheimer's disease risk allele, ApoEε4, potentiates neuronal tau pathology in multiple preclinical models. *Scientific Reports*. 2021;11(1):3438.

52. Zhou X, Shi Q, Zhang X, et al. ApoE4-mediated blood-brain barrier damage in Alzheimer's disease: Progress and prospects. *Brain Research Bulletin*. 2023/07/01/ 2023;199:110670. doi:https://doi.org/10.1016/j.brainresbull.2023.110670

53. Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*. 2017/09/01 2017;549(7673):523-527. doi:10.1038/nature24016

54. Schöll M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. *Molecular and Cellular Neuroscience*. 2019/06/01/ 2019;97:18-33. doi:https://doi.org/10.1016/j.mcn.2018.12.001

55. Chiu MJ, Fan LY, Chen TF, Chen YF, Chieh JJ, Horng HE. Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults. *Front Aging Neurosci*. 2017;9:51. doi:10.3389/fnagi.2017.00051

56. Lue L-F, Pai M-C, Chen T-F, et al. Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects. Original Research.

Frontiers in Aging Neuroscience. 2019-September-03 2019;11doi:10.3389/fnagi.2019.00222

57. Skillbäck T, Farahmand BY, Rosén C, et al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. *Brain*. 2015;138(9):2716-2731. doi:10.1093/brain/awv181

58. Chong JR, Ashton NJ, Karikari TK, et al. Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. *Alzheimers Dement*. Oct 2021;17(10):1649-1662. doi:10.1002/alz.12332

59. Schubert E. Stop using the elbow criterion for k-means and how to choose the number of clusters instead. *SIGKDD Explor Newsl*. 2023;25(1):36–42. doi:10.1145/3606274.3606278

60. Tideman P, Stomrud E, Leuzy A, Mattsson-Carlgren N, Palmqvist S, Hansson O. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. *Neurology*. Apr 12 2022;98(15):e1525-e1533. doi:10.1212/wnl.0000000000013299

61. Harrington MG, Chiang J, Pogoda JM, et al. Executive Function Changes before Memory in Preclinical Alzheimer’s Pathology: A Prospective, Cross-Sectional, Case Control Study. *PLOS ONE*. 2013;8(11):e79378. doi:10.1371/journal.pone.0079378

62. Blennow K. Phenotyping Alzheimer's disease with blood tests. *Science*. 2021;373(6555):626-628. doi:doi:10.1126/science.abi5208

63. Polacchini A, Metelli G, Francavilla R, et al. A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. *Scientific Reports*. 2015/12/10 2015;5(1):17989. doi:10.1038/srep17989

64. Blennow K. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. *Neurology and Therapy*. 2017/07/01 2017;6(1):15-24. doi:10.1007/s40120-017-0073-9

65. Verberk IMW, Misdorp EO, Koelewijn J, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. *Alzheimer's & Dementia*. 2022;18(8):1484-1497. doi:https://doi.org/10.1002/alz.12510

Acknowledgements

This research was supported under the National institutes of Health and National Institute on Aging (grants AG019085, AG019726, and AG058066).

Conflicts

The authors declare no conflicts of interest.

Funding Sources

National institutes of Health and National Institute on Aging (grants AG019085, AG019726, and AG058066).

Consent Statement

All study procedures were approved by the Institutional Review Board at the Case Western Reserve University and University of Miami. Written informed consent was obtained from the participant or legal guardian. For the sake of confidentiality, clinical and genetic data were de-identified according to the study protocol.

Key Words

Alzheimer disease, plasma biomarkers, cognitive function, cluster analysis, founder population

Table 1. Participant characteristics by consensus diagnosis

	CU	MCI	CINAD	AD	
N	754	147	40	126	*p**
Ohio Center, n (%)	413 (54.8)	61 (41.5)	12 (30.0)	66 (52.4)	0.001†
Age, Mean (SD)	80.3 (6.3)	83.1 (4.9)	82.0 (7.9)	83.5 (5.6)	< 0.001‡
Male, n (%)	289 (38.3)	68 (46.3)	22 (55.0)	49 (38.9)	0.07
APOE ε4 Carrier, n (%)	164 (22.2)	36 (25.2)	10 (25.6)	58 (46.4)	< 0.001§
APOE Genotype, n (%)					< 0.001¶
ε2/ε2	0 (0.0)	1 (0.7)	0 (0.0)	0 (0.0)	
ε2/ε3	75 (10.2)	7 (4.9)	5 (12.8)	10 (8.0)	
ε2/ε4	11 (1.5)	2 (1.4)	3 (7.7)	3 (2.4)	
ε3/ε3	499 (67.6)	99 (69.2)	24 (61.5)	57 (45.6)	
ε3/ε4	144 (19.5)	30 (21.0)	7 (17.9)	47 (37.6)	
ε4/ε4	9 (1.2)	4 (2.8)	0 (0.0)	8 (6.4)	
Education, n (%)					0.08¶
< 8 years	56 (7.4)	6 (4.1)	3 (7.5)	16 (12.7)	
8 years	546 (72.4)	114 (77.6)	30 (75.0)	95 (75.4)	
> 9 years	111 (14.7)	25 (17.0)	5 (12.5)	10 (7.9)	

* p-values were obtained from the Kruskal-Wallis, Chi-square or Fisher's exact tests.

† After adjusting for multiple comparisons, the percentage of Ohio residents was significantly higher in the CU group than the MCI or CINAD group.

‡ After adjusting for multiple comparisons, the CU individuals were significantly younger than individuals with MCI or AD.

§ After adjusting for multiple comparisons, the percentage of APOE ε4 carriers was significantly higher in the AD group than the CU or MCI group.

¶ p-value was obtained from the Fisher's exact test.

Abbreviations: SD, standard deviation; CU, cognitively unimpaired; MCI, mild cognitive impairment; AD, Alzheimer disease; CINAD, cognitively impaired but not AD; APOE, apolipoprotein E.

Table 2. Characteristics of pre-fixed number of clusters (k = 2) using plasma Aβ42/Aβ40 and p-tau181

	Cluster 1 (n = 382)	Cluster 2 (n = 294)	*p*
Core Biomarkers, mean (SD)			
Aβ42/Aβ40	0.06 (0.02)	0.04 (0.01)	<0.001
Aβ40	166.29 (66.75)	176.21 (72.58)	0.17
Aβ42	9.23 (3.64)	7.17 (3.46)	<0.001
t-tau	1.81 (0.72)	1.86 (0.67)	0.31
p-tau181	1.71 (0.63)	2.52 (0.79)	<0.001
Demographic and Clinical Characteristics			
Age, mean (SD)	81.69 (5.96)	81.97 (5.52)	0.53
Male, n(%)	146 (38.2)	120 (40.8)	0.55
Center (Ohio), n (%)	132 (34.6)	101 (34.4)	0.99
Education, n (%)			0.33
< 8 years	24 (6.3)	18 (6.1)	
8 years	273 (71.5)	207 (70.4)	
9 - 12 years	61 (16.0)	58 (19.7)	
Smoking, n (%)			0.44
Never	252 (66.0)	204 (69.4)	
<100	50 (13.1)	31 (10.5)	
>100	58 (15.2)	48 (16.3)	
APOE ε2 Carrier, n (%)	45 (11.8)	29 (9.9)	0.39
APOE ε4 Carrier, n (%)	70 (18.3)	103 (35.0)	<0.001
APOE Genotype, n (%)			<0.001
ε2/ε3	40 (10.5)	21 (7.1)	
ε2/ε4	5 (1.3)	8 (2.7)	
ε3/ε3	264 (69.1)	167 (56.8)	
ε3/ε4	64 (16.8)	86 (29.3)	
ε4/ε4	1 (0.3)	9 (3.1)	

Diagnosis, n (%)			0.04
CU	279 (73.0)	191 (65.0)	
MCI	40 (10.5)	48 (16.3)	
CINAD	16 (4.2)	9 (3.1)	
AD	21 (5.5)	27 (9.2)	
Unclear	26 (6.8)	19 (6.5)	

Abbreviations: SD, standard deviation; APOE, apolipoprotein E; CU, cognitively unimpaired; MCI, mild cognitive impairment; CINAD, cognitively impaired but not AD; AD, Alzheimer disease.



Figure 1. Plasma p-tau181, but not Aβ42/Aβ40 ratio, was significantly higher in Amish individuals with AD than CU individuals. Abbreviations: CU, cognitively unimpaired; MCI, mild cognitive impairment; AD, Alzheimer disease; CINAD, cognitively impaired but not AD.



Figure 2. Forest plots illustrating the associations between plasma biomarkers and three clinical outcomes: plasma p-tau181 and the Aβ42/p-tau181 ratio were significantly associated with cognitive preservation when comparing CU individuals to those with CI (including CINAD and AD). A) Multivariate regression models were applied among AD and CU individuals. B) Multivariate regression models were applied among individuals with CU and CI (MCI, CINAD, and AD). C) Multivariate regression models were applied among individuals with CU and CI (CINAD and AD). Abbreviations: AD, Alzheimer disease; CP, cognitive preservation; CU, cognitively unimpaired; MCI, mild cognitive impairment; CINAD, cognitively impaired but not AD.



Figure 3. Clustering analysis based on plasma Aβ42/Aβ40 and p-tau181 levels categorized Amish individuals into two distinct groups (k = 2) with low-risk and high-risk profiles for AD. Abbreviations: CU, cognitively unimpaired; MCI, mild cognitive impairment; CINAD, cognitively impaired but not AD; AD, Alzheimer disease.

	Aβ40	Aβ42	total tau	p-tau181
N of raw samples	1,424	1,424	1,403	1,365
1 No matching clinical data[a]	-12	-12	0	-86
2 Sample check				
- Duplications	-3	-2	-2	-1
- CV% = NaN	-152	-273	-15	-6
- CV% >= 20%	-73	-111	-290	-34
3 Center-specific QC[b]	-259	-134	0	0
4 Outliers	-4	-8	-32	-94
5 Missing diagnosis	-11	-4	-3	-3
N of reminding samples[c]	910	880	701	1,141

Supplemental Figure 1. Biomarker-level quality control. a. Samples had no matching clinical data (i.e., no consensus diagnosis or not Amish). b. Aβ40 and Aβ42 samples before 2014 from Ohio were excluded. c. Samples passed QC include one-time and repeated measurements on the same individual. Abbreviations: QC, quality control; CV, Coefficient of variation percentages.



Supplemental Figure 2. Correlations between the most recently measured plasma biomarkers. Spearman's Rank correlation was performed between biomarker pairs among A) all individuals with a clear diagnosis, B) CU individuals, and C) AD individuals. Pink shading indicates positive correlations, and blue shading indicates negative correlations. The size of the squares indicates varying levels of significance. The darker color indicates a stronger correlation. A statistically significant correlation ($p < 0.001$) after Bonferroni correction is shown by asterisk symbols. Abbreviations: CU, cognitively unimpaired; AD, Alzheimer disease.



Supplemental Figure 3. Determination of the optimal number of clusters using the elbow and silhouette methods. Note: The optimal number of clusters was assessed by the elbow method (Middle) and silhouette width (Right). The curve in the elbow plot started to level off after k = 3 by a visual examination. The highest silhouette width was reached when k = 3, followed by k = 2.

Supplemental Table 1. Comparison of plasma beta-amyloid and tau biomarkers between diagnostic groups.

	CU		MCI		CINAD		AD		
Unit: pg/mL	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	*p**
Aβ42/Aβ40	538	0.052 (0.017)	108	0.049 (0.012)	33	0.053 (0.014)	59	0.049 (0.013)	0.15
p-tau181	656	1.9 (0.8)	122	2.0 (0.9)	30	1.8 (0.9)	106	2.1 (0.9)	0.03†
Additional biomarkers									
Aβ40	558	158.6 (74.5)	112	166.6 (73.5)	33	168.3 (65.1)	61	146.4 (70.2)	0.21
Aβ42	544	7.9 (3.8)	108	8.0 (4.0)	33	8.4 (3.0)	59	7.0 (3.6)	0.26
t-tau	449	1.7 (0.7)	75	1.7 (0.8)	20	1.8 (0.7)	68	1.7 (0.8)	0.78
Aβ42/t-tau	329	5.3 (2.7)	53	5.5 (2.7)	18	5.9 (2.3)	30	5.2 (2.6)	0.52
Aβ42/p-tau181	474	4.8 (2.9)	88	4.6 (2.7)	25	5.5 (2.9)	48	3.6 (2.6)	0.004‡

* p-values were obtained from the Kruskal-Wallis test.

† After adjusting for multiple comparisons, plasma p-tau181 was significantly higher in the AD group than the CU group.

‡ After adjusting for multiple comparisons, the Aβ42/p-tau181 ratio was significantly lower in the AD group compared to CU or CINAD group.

Abbreviations: CU, cognitively unimpaired; MCI, mild cognitive impairment; CINAD, cognitively impaired but not AD; AD, Alzheimer disease; t-tau, total tau.

Supplemental Table 2. Associations between plasma biomarkers and AD-related outcomes.

		AD†				CP with MCI‡				CP without MCI‡			
	Biomarker*	N	OR	95% CI	*p*	N	OR	95% CI	*p*	N	OR	95% CI	*p*
Amyloid biomarkers	Aβ42/Aβ40	583	0.61	(0.20 - 2.18)	0.41	721	1.81	(1.01 - 3.23)	0.05	615	1.76	(0.83 - 3.66)	0.13
	Aβ40	604	0.65	(0.37 - 1.22)	0.15	745	0.89	(0.61 - 1.26)	0.51	636	1.17	(0.75 - 1.77)	0.48
	Aβ42	589	0.69	(0.34 - 1.46)	0.31	727	1.11	(0.78 - 1.59)	0.55	621	1.38	(0.87 - 2.18)	0.17
Tau biomarkers	t-tau	511	1.18	(0.57 - 2.56)	0.66	604	1.00	(0.65 - 1.53)	0.99	531	0.82	(0.46 - 1.41)	0.47
	p-tau181	751	0.77	(0.39 - 1.51)	0.44	900	0.77	(0.53 - 1.13)	0.19	780	0.58	(0.35 - 0.96)	0.04
Aβ/Tau	Aβ42/t-tau	355	0.66	(0.25 - 1.96)	0.43	425	1.38	(0.87 - 2.14)	0.16	373	1.57	(0.83 - 2.90)	0.16
	Aβ42/p-tau181	513	0.86	(0.39 - 1.96)	0.72	624	1.29	(0.93 - 1.77)	0.12	537	1.80	(1.18 - 2.76)	0.01

* Biomarkers were log-transformed.

† Models in predicting AD was adjusted for age, age^2, sex, APOE ε4, time from specimen collection to diagnosis, biomarker batches, research center, and interaction between each biomarker and APOE ε4.

‡ Models in predicting CP was adjusted for age, age^2, sex, APOE ε2, time from specimen collection to diagnosis, biomarker batches, research center, and interaction between each biomarker and APOE ε2.

Abbreviations: AD, Alzheimer disease; CP, cognitive preservation; MCI, mild cognitive impairment; OR, odds ratio; CI, confidence interval.

Supplemental Table 3. Associations between plasma p-tau 181 and AD among APOE ε4 carriers and non-carriers

	Non-Carriers (n = 555)			Carriers (n = 186)		
	OR	95% CI	*p*	OR	95% CI	*p*
Log-transformed p-tau181	0.75	(0.38 - 1.49)	0.41	6.02	(2.33 - 17.11)	< 0.001
Age	1.25	(0.48 - 4.10)	0.69	1.24	(0.41 - 4.59)	0.72
Age^2	0.99	(0.99 - 1.01)	0.89	1.00	(0.99 - 1.01)	0.85
Sex	1.36	(0.76 - 2.43)	0.30	1.31	(0.62 - 2.76)	0.48
Center	3.24	(1.75 - 6.19)	< 0.001	2.09	(0.92 - 4.85)	0.08
Time Diff	0.50	(0.20 - 0.97)	0.08	0.77	(0.35 - 1.18)	0.40

Abbreviations: AD, Alzheimer disease; APOE, apolipoprotein E; OR, odds ratio; CI, confidence interval; Time_Diff, time from sample collection to diagnosis.

Supplemental Table 4. Performance evaluation of plasma biomarkers for AD (distinguishing AD versus CU)

Model	AUC	Sensitivity	Specificity	PPV	NPV
Ref*	0.64	0.53	0.68	0.91	0.20
Ref + APOE ε4	0.72	0.74	0.61	0.92	0.28
Ref + APOE ε4 + individual biomarker					
Aβ42/Aβ40	0.81	0.63	0.88	0.98	0.21
Aβ40	0.80	0.68	0.82	0.97	0.22
Aβ42	0.81	0.68	0.88	0.98	0.23
t-tau	0.71	0.80	0.54	0.92	0.29
p-tau181	0.79	0.64	0.79	0.95	0.26
Aβ42/tTau	0.81	0.67	0.86	0.98	0.19
Aβ42/pTau	0.83	0.58	0.94	0.99	0.18
Ref + APOE ε4 + multiple biomarkers					
Aβ42/40 + p-tau181	0.82	0.58	0.94	0.99	0.19
Aβ40 + Aβ42 + Aβ42/40 + t-tau + p-tau181	0.83	0.72	0.83	0.98	0.20

* The reference model was adjusted for age, age^2, sex, research center, and time from sample collection to diagnosis.

Abbreviations: AD, Alzheimer disease; CU, cognitively unimpaired; Ref, reference model; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; APOE, apolipoprotein E.

Supplemental Table 5. Performance evaluation of plasma biomarkers for cognitive preservation (distinguishing CU versus CI)

	CP with MCI					CP without MCI				
Model	AUC	Sensitivity	Specificity	PPV	NPV	AUC	Sensitivity	Specificity	PPV	NPV
Ref*	0.63	0.49	0.70	0.41	0.77	0.64	0.48	0.74	0.29	0.87
Ref + APOE ε2	0.64	0.59	0.62	0.39	0.79	0.64	0.49	0.74	0.29	0.87
Ref + APOE ε2 + individual biomarker										
Aβ42/Aβ40	0.69	0.62	0.67	0.41	0.83	0.74	0.83	0.55	0.24	0.95
Aβ40	0.68	0.66	0.63	0.40	0.83	0.73	0.72	0.63	0.25	0.93
Aβ42	0.69	0.65	0.62	0.39	0.83	0.74	0.77	0.60	0.24	0.94
t-tau	0.62	0.45	0.40	0.83	0.10	0.63	0.52	0.30	0.83	0.09
p-tau181	0.64	0.68	0.56	0.38	0.82	0.69	0.59	0.71	0.30	0.89
Aβ42/t-tau	0.70	0.95	0.39	0.32	0.96	0.73	0.72	0.63	0.22	0.94
Aβ42/p-tau181	0.69	0.35	0.21	0.81	0.03	0.77	0.38	0.17	0.82	0.03
Ref + APOE ε2 + multiple biomarkers										
Aβ42/40 + p-tau181	0.69	0.64	0.65	0.39	0.84	0.75	0.79	0.62	0.25	0.95
Aβ40 + Aβ42 + Aβ42/40 + t-tau + p-tau181	0.71	0.84	0.49	0.33	0.91	0.77	0.88	0.60	0.23	0.97

* The reference model was adjusted for age, age^2, sex, research center, and time from sample collection to diagnosis.

Abbreviations: CP, cognitive preservation; CI, cognitively impaired; MCI, mild cognitive impairment; Ref, reference model; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value; APOE, apolipoprotein E.

Supplemental Table 6. Comparison of medical history between the pre-fixed number of clusters (k = 2)

Self-reported medical history, n (%)	Cluster 1 (n = 382)	Cluster 2 (n = 294)	*p*
Dementia	14 (3.7)	18 (6.1)	0.09
Parkinson's Disease	6 (1.6)	2 (0.7)	0.09
Multiple Sclerosis	1 (0.3)	3 (1.0)	0.07
Stroke	24 (6.3)	20 (6.8)	0.17
Epilepsy	4 (1.0)	6 (2.0)	0.16
Heart Disease	78 (20.4)	60 (20.4)	0.14
Type1 Diabetes	1 (0.3)	4 (1.4)	0.06
Type2 Diabetes	22 (5.8)	24 (8.2)	0.12
Hypertension	115 (30.1)	90 (30.6)	0.16
Elevated Lipids/Cholesterol	79 (20.7)	47 (16.0)	0.02
Kidney Disease	15 (3.9)	10 (3.4)	0.12
Liver Disease	5 (1.3)	6 (2.0)	0.08
Thyroid Disease	41 (10.7)	30 (10.2)	0.12
Osteoarthritis	140 (36.6)	114 (38.8)	0.16
Osteoporosis	24 (6.3)	20 (6.8)	0.26
Rheumatoid Arthritis	4 (1.0)	7 (2.4)	0.05
Cancer	48 (12.6)	32 (10.9)	0.08
Depression	33 (8.6)	28 (9.5)	0.06

Supplemental Table 7. Pre-fixed number of clusters (k = 2) in relationship to AD-related phenotypes and cognitive function.

Association between clusters and AD-related phenotypes*					
	Sample Size	Cluster 1	Cluster 2		
			OR	95% CI	*p*
AD	509	Ref	1.55	(0.80 - 3.04)	0.19
CP (excluding MCI)	533	Ref	0.60	(0.41 - 0.88)	0.01
CP (including MCI)	620	Ref	0.64	(0.38 - 1.08)	0.09
Association between clusters and cognitive function†					
	Sample Size	Cluster 1	Cluster 2		
			Beta	95% CI	*p*
3MS	657	Ref	0.59	(-0.58 - 1.77)	0.32
Verbal Fluency	451	Ref	0.05	(-0.25 - 0.35)	0.73
Word List Memory	454	Ref	-0.13	(-0.50 - 0.24)	0.48
TMT A	440	Ref	0.20	(-5.30 - 5.69)	0.94
TMT B	425	Ref	1.53	(-14.16 - 11.09)	0.81
Logical Memory I	443	Ref	0.32	(-0.33 - 0.97)	0.34
Logical Memory II	440	Ref	0.14	(-0.46 - 0.74)	0.65
MINT	393	Ref	-0.07	(-0.64 - 0.49)	0.80

* Models were adjusted for age, age^2, sex, research center, and APOE (ε4 for AD and ε2 for CP).

† Models were adjusted for age, age^2, sex, research center, diagnosis, and APOE (ε4 for AD and ε2 for CP).

Abbreviations: AD, Alzheimer disease; CP, cognitive preservation; MCI, mild cognitive impairment; OR, odds ratio; CI,

confidence interval; Ref, reference; APOE, apolipoprotein E; 3MS, the Modified Mini-Mental State Examination; TMT, Trial Making Test; MINT, the Multilingual Naming Test.

Supplemental Table 8. Characteristics of method-derived number of clusters (k = 3) using plasma Aβ42/Aβ40 and p-tau181

	Cluster 1 (n = 228)	Cluster 2 (n = 239)	Cluster 3 (n=211)	*p*
Core Biomarkers, mean (SD)				
Aβ42/Aβ40	0.06 (0.02)	0.05 (0.01)	0.04 (0.01)	< 0.001
Aβ40	165.45 (69.70)	169.24 (63.96)	177.67 (74.75)	0.36
Aβ42	10.01 (3.95)	7.87 (3.16)	7.05 (3.32)	< 0.001
t-tau	1.79 (0.72)	1.84 (0.72)	1.86 (0.66)	0.41
p-tau181	2.20 (0.71)	1.41 (0.41)	2.67 (0.72)	< 0.001
Demographic And Clinical Characteristics				
Age, mean (SD)	81.70 (5.90)	82.00 (5.76)	81.70 (5.66)	0.90
Male, n(%)	75 (33.2)	106 (44.4)	85 (40.3)	0.55
Ohio, n (%)	80 (35.4)	81 (33.9)	72 (34.1)	0.94
Education, n (%)				0.07
< 8 years	10 (4.4)	17 (7.1)	15 (7.1)	
8 years	171 (75.7)	155 (64.9)	154 (73.0)	
9 - 12 years	31 (13.7)	56 (23.4)	32 (15.2)	
Smoking, n (%)				0.47
Never	156 (69.0)	152 (63.6)	148 (70.1)	
<100	28 (12.4)	30 (12.6)	23 (10.9)	
>100	29 (12.8)	47 (19.7)	30 (14.2)	

APOE ε2 Carrier, n (%)	33 (14.9)	21 (8.9)	20 (9.6)	0.09
APOE ε4 Carrier, n (%)	41 (18.5)	48 (20.4)	84 (40.4)	< 0.001
APOE Genotype, n (%)				< 0.001
ε2/ε3	30 (13.3)	18 (7.5)	13 (6.2)	
ε2/ε4	3 (1.3)	3 (1.3)	7 (3.3)	
ε3/ε3	151 (66.8)	169 (70.7)	111 (52.6)	
ε3/ε4	38 (16.8)	43 (18.0)	69 (32.7)	
ε4/ε4	0 (0.0)	2 (0.8)	8 (3.8)	
Diagnosis, n (%)				0.47
CU	165 (73.0)	166 (69.5)	139 (65.9)	
MCI	26 (11.5)	32 (13.4)	30 (14.2)	
CINAD	8 (3.5)	10 (4.2)	7 (3.3)	
AD	14 (6.2)	12 (5.0)	22 (10.4)	
Unclear	13 (5.8)	19 (7.9)	13 (6.2)	

Abbreviations: SD, standard deviation; APOE, apolipoprotein E; CU, cognitively unimpaired; MCI, mild cognitive impairment; CINAD, cognitively impaired but not AD; AD, Alzheimer disease.

Supplemental Table 9. Comparison of medical history between the method-derived number of clusters (k = 3)

Self-reported medical history, n (%)	Cluster 1 (n = 228)	Cluster 2 (n = 239)	Cluster 3 (n=211)	*p*
Dementia	9 (4.0)	9 (3.8)	14 (6.6)	0.56
Parkinson's Disease	3 (1.3)	4 (1.7)	1 (0.5)	0.35
Multiple Sclerosis	0 (0.0)	2 (0.8)	2 (0.9)	0.41
Stroke	13 (5.8)	14 (5.9)	17 (8.1)	0.69
Epilepsy	1 (0.4)	4 (1.7)	5 (2.4)	0.28
Heart Disease	45 (19.9)	50 (20.9)	43 (20.4)	0.24
Type1 Diabetes	1 (0.4)	1 (0.4)	3 (1.4)	0.45
Type2 Diabetes	10 (4.4)	17 (7.1)	19 (9.0)	0.19
Hypertension	68 (30.1)	70 (29.3)	67 (31.8)	0.69
Elevated Lipids/Cholesterol	50 (22.1)	45 (18.8)	31 (14.7)	0.12
Kidney Disease	11 (4.9)	7 (2.9)	7 (3.3)	0.51
Liver Disease	6 (2.7)	0 (0.0)	5 (2.4)	0.10
Thyroid Disease	29 (12.8)	23 (9.6)	19 (9.0)	0.40
Osteoarthritis	84 (37.2)	87 (36.4)	83 (39.3)	0.70
Osteoporosis	22 (9.7)	11 (4.6)	11 (5.2)	0.07
Rheumatoid Arthritis	3 (1.3)	4 (1.7)	4 (1.9)	0.53
Cancer	28 (12.4)	29 (12.1)	23 (10.9)	0.79
Depression	10 (4.4)	29 (12.1)	22 (10.4)	0.01

Supplemental Table 10. Method-derived number of clusters (k = 3) in relationship to AD-related phenotypes and cognitive function.

Association between clusters and AD-related phenotypes*								
	Sample Size	Cluster 1	Cluster 2			Cluster 3		
			OR	95% CI	*p*	OR	95% CI	*p*
AD	509	Ref	0.66	(0.28 - 1.57)	0.35	1.24	(0.56 - 2.79)	0.59
CP (excluding MCI)	533	Ref	1.05	(0.54 - 2.06)	0.88	0.59	(0.31 - 1.12)	0.11
CP (including MCI)	620	Ref	0.94	(0.59 - 1.51)	0.81	0.69	(0.43 - 1.11)	0.13
Association between clusters and cognitive function†								
	Sample Size	Cluster 1	Cluster 2			Cluster 3		
			Beta	95% CI	*p*	Beta	95% CI	*p*
3MS	657	Ref	-0.69	(-2.07 - 0.68)	0.32	-0.13	(-1.58 - 1.33)	0.87
Verbal Fluency	451	Ref	0.21	(-0.14 - 0.57)	0.24	0.08	(-0.28 - 0.45)	0.66
Word List Memory	454	Ref	-0.11	(-0.56 - 0.33)	0.61	-0.14	(-0.59 - 0.32)	0.55
TMT A	440	Ref	1.84	(-4.74 - 8.41)	0.58	3.18	(-3.53 - 9.89)	0.35
TMT B	425	Ref	4.50	(-10.59 - 19.59)	0.56	15.81	(0.53 - 31.09)	0.04
Logical Memory I	443	Ref	0.20	(-0.58 - 0.98)	0.61	0.39	(-0.40 - 1.19)	0.33
Logical Memory II	440	Ref	-0.01	(-0.72 - 0.70)	0.97	-0.04	(-0.78 - 0.69)	0.91
MINT	393	Ref	-0.34	(-1.01 - 0.34)	0.33	-0.35	(-1.03 - 0.34)	0.32

* Models were adjusted for age, age^2, sex, research center, and APOE (ε4 for AD and ε2 for CP).

† Models were adjusted for age, age^2, sex, research center, diagnosis, and APOE (ε4 for AD and ε2 for CP).

Abbreviations: AD, Alzheimer disease; CP, cognitive preservation; MCI, mild cognitive impairment; OR, odds ratio; CI, confidence interval; Ref, reference; APOE, apolipoprotein E; 3MS, the Modified Mini-Mental State Examination; TMT, Trial Making Test; MINT, the Multilingual Naming Test.